PressMarch 21, 2022 Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities
PressMarch 18, 2022 Optimi Health Begins Cultivation Of Natural Psilocybin For Use In Clinical Trials
PressMarch 17, 2022 Awakn Life Sciences Receives Regulatory to Begin Delivering Treatments in London Clinic
PressMarch 15, 2022 Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
PressMarch 11, 2022 Albert Labs Closes $4.7m Private Placement; Begins Trading On The Canadian Securities Exchange
PressMarch 10, 2022 Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets
PressMarch 4, 2022 Magellan Rx Management Releases Clinical Insights on the Use of Psychedelics in Treating Mental Health Conditions
PressMarch 4, 2022 Love Pharma Updates Microdoz Proposed Acquisition with Global Leader in Psychedelic Research
PressFebruary 25, 2022 HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research
PressFebruary 24, 2022 COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
PressFebruary 23, 2022 PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma
PressFebruary 22, 2022 World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
PressFebruary 18, 2022 Awakn Life Sciences Drug Discovery Program Files Patent Application for a New Class of Entactogen-Like Molecules
PressFebruary 17, 2022 Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
